timothy sykes logo
CMPX Rises As Compass Therapeutics Sets Key Cancer Data Webcast Thumbnail
G Google News

CMPX Rises As Compass Therapeutics Sets Key Cancer Data Webcast

ELLIS HOBBS•UPDATED APR. 25, 2026, 11:07 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Compass Therapeutics Inc. stocks have been trading up by 8.25 percent following upbeat sentiment around its latest clinical trial progress.

Candlestick Chart

Weekly Update Apr 20 – Apr 24, 2026: On Saturday, April 25, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending up by 8.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Compass Therapeutics (CMPX) is a clinical-stage oncology name with no commercial revenue and deeply negative profitability (ROE ~-41%, ROA ~-37%), typical for its stage but still capital-intensive. Balance sheet strength is a clear positive: cash, equivalents, and short-term investments of ~$209M versus only ~$23M in total liabilities support a very low ~0.05 debt-to-equity and current ratio near 15. Quarterly operating cash burn of ~$13M implies a multi-year runway, limiting near-term financing risk despite negative EBITDA of ~$19.8M.

Technically, CMPX is in a short-term uptrend after a strong weekly move from a 5.03 low to a 5.64 close, breaking above the recent 5.40–5.45 congestion. Five‑minute candles into the close show buyers controlling dips, with higher lows forming above 5.30 and increasing volume on pushes through 5.50, confirming accumulation rather than a one-day spike. For near-term trading, 5.30 is the key actionable level: aggressive longs buy pullbacks toward 5.30 with a stop near 5.05, targeting 6.00.

The announced April 27, 2026 webcast for topline secondary endpoint data from COMPANION-002 in advanced biliary tract cancer is the critical near-term catalyst and will likely drive event-driven volatility. Versus broader Healthcare and Biotech/Life Sciences indices, CMPX offers higher binary risk but also superior upside if efficacy and durability are confirmed. Given strong cash, low leverage, and favorable tape, I assign a bullish outlook with near-term support at 5.30, resistance at 6.25, and a 6–9 month price target of 7.50.

Quick Financial Overview

CMPX has shown a constructive weekly price move into the April 27, 2026 webcast catalyst. Over the recent week, price dipped from the low $5.40 area toward $5.03 before snapping back and closing near $5.64. That close marks a solid push off the lows and above the early-week range, which often signals accumulation ahead of an event. Intraday, the stock briefly flushed under $5.00 to about $4.90 and then recovered back above $5.00, showing both volatility and dip buying.

Under the hood, Compass Therapeutics Inc. is still a development-stage biotech with negative earnings. The latest quarterly data show net income of about -$15.7M and EBITDA near -$19.8M, driven mainly by research and development expense of roughly $13.7M. Cash flow from operations was around -$13.3M, but the company ended the period with about $31.2M in cash and roughly $208.9M when you include cash and short-term investments, providing a runway for clinical work.

More Breaking News

Key ratios confirm the high-risk, research-focused profile. Returns on equity and assets are deeply negative, reflecting heavy spend without approved products yet. However, financial strength metrics are unusually solid for a small biotech: current and quick ratios near 15, total debt to equity about 0.05, and long-term debt under $9M against equity of about $196.8M. With enterprise value around $706.8M and price to book near 4.77, traders are paying up for pipeline potential, especially the COMPANION-002 program.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading CMPX

Millionaire's
POV on CMPX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”